Research Group
Prostate and Urologic Cancer
Sponsor
University of Illinois at Chicago
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01594502
The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.
Intervention
Dutasteride, Placebo
Condition
Prostate Cancer
Investigators
Peter H Gann, MD, ScD